Compare Abbott India with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 50.5 19.6 257.2% View Chart
P/BV x 15.0 2.2 681.7% View Chart
Dividend Yield % 0.5 0.7 62.6%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
CIPLA
Mar-19
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs8,834678 1,303.0%   
Low Rs5,458484 1,128.0%   
Sales per share (Unadj.) Rs1,731.1198.2 873.3%  
Earnings per share (Unadj.) Rs211.918.5 1,144.1%  
Cash flow per share (Unadj.) Rs219.935.0 628.5%  
Dividends per share (Unadj.) Rs65.003.00 2,166.7%  
Dividend yield (eoy) %0.90.5 176.1%  
Book value per share (Unadj.) Rs945.2186.3 507.3%  
Shares outstanding (eoy) m21.25805.70 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.9 140.9%   
Avg P/E ratio x33.731.4 107.5%  
P/CF ratio (eoy) x32.516.6 195.7%  
Price / Book Value ratio x7.63.1 242.5%  
Dividend payout %30.716.2 189.4%   
Avg Mkt Cap Rs m151,848468,031 32.4%   
No. of employees `0003.522.6 15.4%   
Total wages/salary Rs m4,35628,565 15.2%   
Avg. sales/employee Rs Th10,555.57,053.1 149.7%   
Avg. wages/employee Rs Th1,249.91,261.5 99.1%   
Avg. net profit/employee Rs Th1,292.2659.1 196.1%   
INCOME DATA
Net Sales Rs m36,786159,710 23.0%  
Other income Rs m1,1334,766 23.8%   
Total revenues Rs m37,919164,475 23.1%   
Gross profit Rs m6,04730,973 19.5%  
Depreciation Rs m16913,263 1.3%   
Interest Rs m231,684 1.3%   
Profit before tax Rs m6,98920,791 33.6%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4855,695 43.6%   
Profit after tax Rs m4,50314,924 30.2%  
Gross profit margin %16.419.4 84.8%  
Effective tax rate %35.627.4 129.8%   
Net profit margin %12.29.3 131.0%  
BALANCE SHEET DATA
Current assets Rs m27,610124,266 22.2%   
Current liabilities Rs m8,56937,715 22.7%   
Net working cap to sales %51.854.2 95.5%  
Current ratio x3.23.3 97.8%  
Inventory Days Days6091 66.4%  
Debtors Days Days2795 28.9%  
Net fixed assets Rs m1,057105,190 1.0%   
Share capital Rs m2131,611 13.2%   
"Free" reserves Rs m19,873148,511 13.4%   
Net worth Rs m20,086150,123 13.4%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m29,409239,633 12.3%  
Interest coverage x311.613.3 2,335.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 187.7%   
Return on assets %15.46.9 222.0%  
Return on equity %22.49.9 225.5%  
Return on capital %34.911.8 294.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36957,410 0.6%   
Fx outflow Rs m4,91819,041 25.8%   
Net fx Rs m-4,54938,368 -11.9%   
CASH FLOW
From Operations Rs m4,99116,911 29.5%  
From Investments Rs m-2,570-16,687 15.4%  
From Financial Activity Rs m-1,428-3,487 40.9%  
Net Cashflow Rs m993-3,451 -28.8%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Mar 27, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS